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Abstract
Background: This study examined the attitudes and actions of 3415 physician-recruited adults
aged ≥ 16 years with asthma in eleven countries who were prescribed regular maintenance therapy
with inhaled corticosteroids or inhaled corticosteroids plus long-acting β2-agonists.
Methods: Structured interviews were conducted to assess medication use, asthma control, and
patients' ability to recognise and self-manage worsening asthma.
Results: Despite being prescribed regular maintenance therapy, 74% of patients used short-acting
β2-agonists daily and 51% were classified by the Asthma Control Questionnaire as having
uncontrolled asthma. Even patients with well-controlled asthma reported an average of 6
worsenings/year. The mean period from the onset to the peak symptoms of a worsening was 5.1
days. Although most patients recognised the early signs of worsenings, the most common response
was to increase short-acting β2-agonist use; inhaled corticosteroids were increased to a lesser
extent at the peak of a worsening.
Conclusion: Previous studies of this nature have also reported considerable patient morbidity, but
in those studies approximately three-quarters of patients were not receiving regular maintenance
therapy and not all had a physician-confirmed diagnosis of asthma. This study shows that patients
with asthma receiving regular maintenance therapy still have high levels of inadequately controlled
asthma. The study also shows that patients recognise deteriorating asthma control and adjust their
medication during episodes of worsening. However, they often adjust treatment in an
inappropriate manner, which represents a window of missed opportunity.
Background
Asthma affects 300 million people worldwide [1], with
increasing prevalence in Western Europe and the USA in
particular. International guidelines stipulate goals for
optimising asthma management, such as preventing
chronic symptoms, minimising exacerbations and emer-
gency care, minimising the use of rescue β2-agonists and
maintaining normal levels of physical activity [2].
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The therapeutic options available for patients with asthma
depend on the severity of the condition [2-4]. Mainte-
nance therapy with inhaled corticosteroids (ICS) is advo-
cated for all patients with persistent asthma in order to
control airway inflammation, with the addition of a long-
acting β2-agonist (LABA) for patients who remain sympto-
matic on an ICS alone. ICS/LABA combination inhalers
are more convenient for patients [5] and have been shown
to produce effective asthma control in clinical trials [6-8].
In recent years, several patient surveys have attempted to
gain insight into levels of asthma control and into patient
preferences regarding asthma management [9,10]. The
majority of patients in those studies, however, were
selected from the general population and had mild inter-
mittent or mild persistent asthma – and notably, not all
patients had a physician-confirmed diagnosis – with over
75% of adult patients not using any regular ICS therapy.
Rabe and co-workers have shown that among these
patients – the majority of whom were not taking prevent-
ative therapy – asthma control is poor and does not meet
guideline targets [11,12].
Studies involving patients receiving regular maintenance
therapy have not been reported previously. The Interna-
tional Asthma Patient Insight Research (INSPIRE) study is
the first multinational study to focus on patients with a
physician-confirmed diagnosis of asthma who were
receiving regular maintenance therapy with ICS, with or
without a LABA. The study aimed to assess patients' atti-
tudes to asthma management, levels of asthma control
and the impact of the condition on patients' lives, as well
as to establish the frequency and severity of worsenings
and, most importantly, how patients respond to such
events.
Methods
Study design
The study design was based on recruitment of patients by
physicians, a method that provides strict controls on sam-
pling and all other aspects of patient selection. This was a
quantitative research programme utilising telephone data
collection methods.
Selection of physicians
The study was conducted between October 2004 and
August 2005 in eleven countries (Australia, Belgium, Can-
ada, France, Germany, Italy, Spain, Sweden, The Nether-
lands, UK and USA). Fifty physicians were recruited in
each country except Germany (n = 64), Canada (n = 43)
and the USA (n = 74). Primary care physicians (PCPs) and
specialists (not paediatricians) were eligible, and only
physicians who were either office-based or office- and
hospital-based were recruited. All physicians saw a mini-
mum number of patients each month (n ≥ 20 for PCPs; n
≥ 40 for specialists) and had not participated in asthma-
related research in the 3 months before study entry. Phy-
sicians were eligible if they were aged 30–59 years and had
been qualified for between 2 and 30 years. Quotas on
physician type (specialist vs PCP), age, years qualified,
gender and region were imposed. All physicians and
patients who were recruited into the study received a pay-
ment for their time and involvement.
Inclusion criteria
Patients were selected according to the research hypothe-
sis, ie on the basis of their use of ICS medication either as
monotherapy or in combination with another medica-
tion. Physicians were asked to identify patients with
asthma who were aged ≥ 16 years, had a physician diagno-
sis of asthma and were attending the clinic either for a
consultation or to collect a prescription for asthma medi-
cation. To minimise selection bias, physicians were
requested to ask their next ten consecutive patients with
asthma if they would participate in a telephone interview.
This was to ensure a random selection of patients and
guarantee a sufficient number of patients to undertake six
successful interviews per physician. All patients had to
have received a prescription for maintenance therapy with
ICS, with or without LABA (including ICS/LABA combina-
tion therapy). Patients with chronic obstructive pulmo-
nary disease were excluded but smokers were not.
Physicians reported each patient's prescribed asthma
medication.
All eligible patients received an invitation card. This card
contained a serial number unique to each patient, which
the patient was required to read out during the subse-
quent telephone interview. Patients were asked to sign a
consent form and were informed that their details would
remain strictly confidential and that information col-
lected during the study would not be passed on to any
third party, including their physician. Owing to restrictive
privacy legislation in Germany, prescribing information
was collected during the patient interviews.
The study was conducted in accordance with the confi-
dentiality guidelines stipulated in the International
Chamber of Commerce/European Society for Opinion
and Marketing Research (ICC/ESOMAR) and European
Pharmaceutical Market Research Association (EphMRA)
codes of conduct, and conformed to national legislation
pertaining to confidentiality and data protection in each
country.
Telephone interviews
Telephone interviews (average duration 30 min) were per-
formed using a structured questionnaire. Interviews were
conducted by local interviewers on behalf of the GfK Mar-BMC Pulmonary Medicine 2006, 6:13 http://www.biomedcentral.com/1471-2466/6/13
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tin Hamblin research agency (London, UK) in the
patient's native language.
The English version of the questionnaire was translated
into the patient's native language, proof-read by an inde-
pendent proof-reader to verify its accuracy and validated
using pilot interviews.
Respondents were asked about their use of asthma ther-
apy; need for medical intervention for asthma (defined as
a visit to an emergency room, and/or hospital admission,
and/or an unscheduled visit to the PCP, and/or a course
of steroid tablets) in the last year; incidence of asthma
worsenings (defined as occasions when asthma symp-
toms had become bothersome or hindering) in the past
year; perceived asthma control; and activity limitations
due to asthma.
Asthma control
The Asthma Control Questionnaire (ACQ; 6-item version
with forced expiratory volume in 1 s question omitted)
[13,14] was used to assess asthma control. Patients were
asked to recall their experiences over the past 7 days and
respond to each question on a 7-point Likert scale, where
0 represents no impairment and 6 represents maximum
impairment. Patients were defined as having well-control-
led asthma (ACQ score < 0.75); not well-controlled
asthma (ACQ score 0.75–1.5), or uncontrolled asthma
(ACQ score > 1.5), as previously reported [15].
Results
Sample population
Seventy-seven per cent of the physicians recruited were
PCPs and 23% were specialists. Of the 3893 patients
enrolled, full interviews were completed by 3415 patients
(Figure 1). Patient demographic data are shown in Table
1. The eleven national samples of asthma patients showed
similar age and gender distributions, and overall results
appeared to be generally very consistent across the
national samples (data not shown).
Thirty per cent of patients were using ICS alone when well
and the remaining 70% were prescribed ICS/LABA (61%
used a combination inhaler and 9% used separate inhal-
ers). The mean number of visits that patients had made to
their physician or asthma nurse in the past year was 4.98.
Asthma control
Despite all patients being prescribed regular ICS for main-
tenance therapy and a high proportion of patients using
concomitant LABA, 74% of patients reported using at least
one inhalation of short-acting β2-agonist (SABA) rescue
therapy every day during the 7 days before the interview
took place. Fifty-one per cent of patients reported having
needed unplanned medical care (such as hospitalisation)
as a result of an asthma attack on at least one occasion in
the last year. Patients had had an average of 3.1 asthma-
related unscheduled medical interventions in the year
prior to the study.
Using overall ACQ scores to classify patients' general level
of asthma control [15], 51% of patients were classified as
Patient flow Figure 1
Patient flow. *Other reasons for noncompletion included: 
patients did not have asthma; patients were under 16 years 
of age; patients used preventer only; or patients had commu-
nication difficulties.
Table 1: Patient demographics and characteristics
Characteristic Patients (n = 3415)
Male, % 35
Mean age ± SD, years 45.2 ± 16.7
Recruitment of patients*, n (%)
PCP 2600 (76)
Specialist 785 (23)
Mean asthma duration, years 16.0
Current smokers, n (%) 714 (21)
Daily maintenance therapy prescribed, n (%)†
ICS no LABA 1018 (30)
ICS plus LABA 2393 (70)
Budesonide/formoterol 769 (23)
Salmeterol/fluticasone 1305 (38)
Self-assessed overall health when feeling well, n 
(%)
Very good 1627 (48)
Good 1221 (36)
Average 431 (13)
Bad 87 (3)
Very bad 49 (1)
Self-assessed asthma level over previous 7 days 
versus general level‡, n (%)
Relatively good 2498 (73)
Relatively bad 871 (26)
Definition of abbreviations: ICS=inhaled corticosteroids; LABA=long-
acting β2-agonist;
SD=standard deviation.
*Data not available for 30 patients. †Data not available for 4 patients. 
Data not available for 46 patients.BMC Pulmonary Medicine 2006, 6:13 http://www.biomedcentral.com/1471-2466/6/13
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having uncontrolled asthma, 21% had asthma that was
not well controlled and only 28% of patients were classi-
fied as having well-controlled asthma [15].
Most patients (n = 3047 [89%]) experienced periods of
worsenings during the last year (mean 11.8/year) (Figure
2). Even patients with well-controlled asthma reported an
average of 6.3 worsenings/year. Overall, 42% of patients
rated their most recent worsening as severe, 45% rated it
as moderate and 13% as mild. On average, patients
reported that 27% of the worsenings that they had experi-
enced in the last year were severe.
Patients' own perceptions of how good their level of
asthma control was during the week preceding the inter-
view contrasted with the ACQ findings. Of those patients
with asthma that was not well controlled according to the
ACQ, 87% classed their asthma control during the week
preceding the interview as "relatively good"; furthermore,
55% of patients classified as having uncontrolled asthma
rated their asthma as being "relatively good".
Asthma variability and patient response
The majority of patients (84%) recognised that they had
experienced variation in their asthma during the past year.
When asked whether they perceived any signs or warnings
that they were about to experience a worsening of asthma,
68% of patients said that they were able to identify such
signs. When described, these signs or warnings were
found to correspond to asthma symptoms, the most com-
mon being "shortness of breath/getting breathless". Of
the patients who reported recognising signs of an impend-
ing worsening, the mean length of time from the appear-
ance of the first signs to the peak symptoms of the
worsening was 5.1 days (range: ≤ 30 minutes to > 2
weeks). The mean length of time from peak symptoms to
recovery was 6.2 days.
Patients responded to the signs of an impending worsen-
ing by increasing their medication. Regardless of the type
of maintenance therapy they were prescribed, patients
reported using their SABA at the onset of symptoms, with
the ICS being increased later and to a lesser extent when
symptoms were at their worst (Figures 3a and 3b). A ≥ 4-
fold increase in the number of SABA inhalations was
reported when symptoms were at their peak compared
with when patients were well. When symptoms started to
decrease, patients reduced their intake of both SABA and
ICS.
Although only 29% of patients stated that their physician
had instructed them to step up their maintenance medica-
tion in response to worsening asthma, 52% of patients
stated that they increased the dose regardless of what they
had been advised. Fewer patients underused their mainte-
nance medication when they experienced worsening
asthma compared with when they felt well (Figure 4).
Patient attitudes to asthma management
A total of 2992 patients (88%) stated that they were very
or quite confident that they could self-manage their
asthma worsenings without physician visits. Many
patients (n = 1858 [54%]) were concerned about taking
too much medication when they felt well or during peri-
ods with no symptoms (Table 2). The majority of patients
reported that they used their medication as and when nec-
essary and were much more likely to try to manage their
asthma themselves, rather than consulting their physi-
cian, when symptoms become bothersome (Table 2).
Nearly 70% of patients also agreed that they preferred to
adjust their maintenance ICS/combination medication to
the changes in their asthma, i.e. taking less medication
when well and more when their asthma worsens (Table
2). Ninety per cent of patients (n = 3075) stated that they
wanted immediate relief from symptoms and 85% (n =
2898) felt confident that they knew their asthma well
enough to intervene early to try to prevent a worsening of
symptoms.
Impact of asthma on patients' lives
Despite a prescription for daily maintenance therapy with
ICS ± LABA, worsening asthma symptoms were found to
affect all aspects of patients' daily lives, particularly their
leisure and social commitments (Table 3). Over 70% of
patients stated that the worst drawbacks of having asthma
were the interference in their daily lives and the panic they
The number of worsenings experienced by patients who had  had ≥ 1 worsening in the last year, by level of Asthma Con- trol Questionnaire-defined asthma control Figure 2
The number of worsenings experienced by patients who had 
had ≥ 1 worsening in the last year, by level of Asthma Con-
trol Questionnaire-defined asthma control. A worsening was 
defined as an occasion when asthma symptoms had become 
bothersome or hindering in the past year. The mean number 
of worsenings for the total population was 11.8/year.BMC Pulmonary Medicine 2006, 6:13 http://www.biomedcentral.com/1471-2466/6/13
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(a) Use of short-acting β2-agonist (SABA) rescue medication and (b) use of inhaled corticosteroid (ICS) maintenance medica- tion during the different stages of an asthma worsening Figure 3
(a) Use of short-acting β2-agonist (SABA) rescue medication and (b) use of inhaled corticosteroid (ICS) maintenance medica-
tion during the different stages of an asthma worsening. All patients used ICS plus a separate long-acting β2-agonist (LABA), ICS 
alone, or a combination ICS/LABA product for regular maintenance therapy. Data are based on all patients who reported using 
each medication type at each particular stage.BMC Pulmonary Medicine 2006, 6:13 http://www.biomedcentral.com/1471-2466/6/13
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felt as their symptoms increased (Table 4), indicating the
impact of the disease on patients' health-related quality of
life.
Discussion
This study is the first to examine the perceptions of
asthma among physician-recruited patients receiving
daily maintenance therapy with ICS ± LABA. The results
from this study emphasise the extent to which asthma
management needs to improve in this group of patients.
The previously published Asthma Insights and Reality in
Europe (AIRE) survey indicated that only a small propor-
tion of patients achieve guideline targets for asthma con-
trol [11]; however, the majority of patients in that survey
had mild asthma and ICS maintenance therapy was only
used by 25% of adult patients [11]. In our study, we have
shown that asthma control is also suboptimal in patients
receiving regular maintenance therapy. Despite 70% of
our patients being prescribed therapy with ICS plus LABA,
only 28% had well-controlled asthma according to their
ACQ scores, with 51% of patients classified as having
uncontrolled asthma. Most patients (89%) experienced
periods of worsenings within the last year (mean 12/
year). Even patients with well-controlled asthma reported
an average of 6 worsenings/year. Although one of the Glo-
bal Initiative for Asthma guideline definitions of asthma
control is the minimal use of as-needed β2-agonists [2],
74% of patients used their SABA rescue therapy every day
in the week preceding the interview. Additionally, 51% of
patients had required medical intervention for their
asthma at least once in the past year, further demonstrat-
ing the poor level of asthma control. Theoretically, this
could reflect therapy-resistant disease or an underestima-
tion of disease severity by doctors and prescription of
insufficient medication. Other possible explanations
include underuse of medication by patients or their fail-
ure to recognise deteriorating asthma and adjust their
medication. Regardless of the cause, a large proportion of
patients had suboptimally controlled asthma.
Asthma was shown to impact on all aspects of patients'
lives. In particular, patients referred to the panic or fear
they have when their symptoms increase, emphasising the
Table 4: Patients' reported worst drawbacks of having asthma 
(scale: disagree strongly, disagree somewhat, agree somewhat, 
agree strongly [data for patients who agreed with each 
statement are presented])
Drawback No. of patients (%) 
(n = 3415)
The panic I feel when symptoms start to become 
bothersome
2477 (73)
The interference with my daily life 2490 (73)
The thought of having to go to the emergency 
room/hospital
1835 (54)
Having a sudden attack in front of my children, 
friends and others
1751 (51)
The thought of feeling different from other 
people
948 (28)
Table 2: Patients' (n = 3415) attitudes to asthma management (scale: disagree strongly, disagree somewhat, agree somewhat, agree 
strongly [data for patients who agreed with each statement are presented])
Attitude statement Agree somewhat n (%) Agree strongly n (%)
I want to take treatments that provide immediate relief 577 (17) 2498 (73)
I use my medication as and when necessary 530 (16) 2240 (66)
I am confident I know my asthma well enough to intervene early to try and prevent worsening 
symptoms
829 (24) 2069 (61)
I prefer to adjust my maintenance ICS/combination medication to the changes of my asthma, taking 
less when feeling well and more when feeling worse
624 (18) 1723 (50)
I am concerned about taking too much medication when I am well 719 (21) 1139 (33)
Despite taking my medication as my doctor tells me to, I still have a fear of having a serious asthma 
attack
682 (20) 1000 (29)
When I feel well, I believe there is no need to take my medication every day 464 (14) 837 (25)
I would prefer to take a high dose of ICS/combination medication to try to avoid as many 
symptoms as possible
588 (17) 626 (18)
I am much more likely to try to manage my asthma myself, rather than visit my physician as soon as 
my symptoms become bothersome
804 (24) 1601 (47)
I am concerned about taking higher doses of medication due to possible side effects 792 (23) 1246 (36)
Table 3: Proportion of patients reporting that worsening asthma 
limited/prevented their daily activities
Activity No. of patients (%) (n = 3415)
Exercise and physical activity 2476 (73)
Leisure activities 1671 (49)
Social commitments 1340 (39)
Intimacy with partner 999 (29)
Work 973 (28)
Time spent with family 535 (16)BMC Pulmonary Medicine 2006, 6:13 http://www.biomedcentral.com/1471-2466/6/13
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significant emotional burden of asthma. Asthma's inter-
ference with daily activities was reported by most patients
to be the worst part of having the disease. These restric-
tions imposed by asthma demonstrate the extent to which
poor control affects patients' health-related quality of life.
There was a discrepancy between the level of asthma con-
trol demonstrated by the ACQ questionnaire and patients'
perceived level of control. These data show that even
patients prescribed maintenance medication and with
recent physician contact tend to underestimate their
asthma symptoms and tolerate suboptimal control. This
situation may reflect a lack of information from PCPs and
nurses and a lack of regular contact with medical profes-
sionals [10]. Alternatively, it may be that patients consider
their level of symptoms to be acceptable and are moti-
vated to take the least "effective" dose of their medication.
Indeed, patients stated that taking too much medication
during periods with no symptoms was a concern. Addi-
tionally, guidelines do emphasise the need for patients to
be prescribed the lowest dose of medication that controls
the disease [2] and some studies suggest that overtreat-
ment with ICS is not uncommon [16].
Most patients reported experiencing early warning signs –
symptoms such as breathlessness – before periods of
worsening asthma. The mean period from the occurrence
of these early signs to the peak of a worsening was approx-
imately 5 days and was followed by a recovery period of
similar length. This time period from the onset of initial
symptoms to an exacerbation, or worsening, is in line
with observations from the FACET study. Tattersfield and
co-workers [17] showed that in the FACET study, patient-
reported asthma symptom scores increased and peak
expiratory flow decreased in the days before an asthma
exacerbation, returning to previous levels in the days after
the event. Such a period of worsening symptoms is likely
to represent a window of opportunity, during which
patients could intervene early by increasing their asthma
medication to prevent further worsening of symptoms.
Our data demonstrate that patients try to intervene early
in response to signs of an impending worsening by
increasing their intake of medication, and fewer patients
underused their maintenance medication during such
periods. However, the current study highlights a missed
opportunity, as patients tended to adjust their therapy in
a suboptimal manner – increasing their intake of SABA
when symptoms first appear, but only increasing their ICS
dose when symptoms had continued to worsen, at the
peak of an asthma attack. Despite controversy regarding
the benefit of increasing the dose of ICS when asthma
deteriorates [18,19], an extensive review has shown that
providing patients with individual written asthma action
plans, with advice to double or treble the dose of ICS, can
reduce symptoms and unscheduled use of healthcare
resources [20]. Evidence suggests that intervening early
with ICS or ICS/LABA medication provides better long-
term asthma control [21-24]. Thus, the failure of patients
to increase their ICS in response to early symptoms may
be an important factor contributing to frequent worsen-
ings and suboptimal asthma control. The finding that
Patient compliance with their regular maintenance medication when feeling well and during asthma worsenings Figure 4
Patient compliance with their regular maintenance medication when feeling well and during asthma worsenings. Definitions 
were as follows: Compliant Minus: using less maintenance medication than prescribed; Compliant: using maintenance medica-
tion as prescribed; Compliant Plus: using more maintenance medication than prescribed.BMC Pulmonary Medicine 2006, 6:13 http://www.biomedcentral.com/1471-2466/6/13
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patients express an ability and willingness to alter asthma
therapy themselves – but adjust the wrong medication
type at the onset of worsenings – suggests failure in the
implementation of the self-management education that
has been recommended by guidelines for over 15 years
[25].
During periods of worsening asthma, treatment regimens
whereby patients increase their ICS/LABA maintenance
dose in line with a self-management plan have been dem-
onstrated to improve asthma control compared with
fixed-dose combination therapy plus SABA [22,26]. A
subsequent review found that stating when to increase ICS
and when to start taking oral steroids are key features for
inclusion in patient action plans [27]. Self-management
action plans have been shown to improve asthma-specific
quality of life, as patients feel less anxious about the influ-
ence of asthma on their daily activities [28] and self-man-
agement plans may also enhance patient compliance [29].
In our study, the majority of patients stated that they dis-
liked the uncertainty associated with asthma exacerba-
tions, but felt confident about self-managing their asthma
and intervening early by increasing their medication.
These results are in keeping with previous data demon-
strating that patients feel comfortable adjusting their own
medication without recourse to a healthcare professional
[10]. From our study, it is clear that the impact of asthma
on patients remains considerable, in terms of increased
anxiety, dislike of uncertainty, interference with normal
activities, fear of being hospitalised and fear of having
attacks in front of their family (Table 4). Twenty-eight per
cent of respondents described feeling stigmatised by their
asthma, a proportion remarkably similar to that reported
17 years ago in a smaller interview/questionnaire-based
study despite the apparent increase in public awareness of
asthma over the past two decades [30].
The study recruited patients who had recently visited their
physician's clinic, either for consultation or to receive a
prescription. This inclusion criterion potentially excluded
patients with poor access to medical care – often associ-
ated with lower socioeconomic status and increased dis-
ease morbidity [31]. As a result of excluding such patients,
the level of asthma control across the globe may be worse
than identified by our findings. Conversely, the inclusion
of patients who had recently attended their physician's
clinic may have introduced a bias towards those with
more severe disease. It is also possible that some patients
may have had chronic obstructive pulmonary disease
rather than asthma, therefore giving the impression of
more severe symptoms. However, the chances of misdiag-
nosis in the present study should be lower as patients were
recruited by physicians rather than by telephone or direct
door-to-door recruitment, as in previous studies. The
intention of this study was to recruit patients typically
seen in everyday practice and these results are, therefore,
applicable to the practicing physician. One of the
strengths of this study is the insight that it offers into
patients' attitudes and actions across eleven different
countries in three continents. Despite the geographical
spread, the results appeared to be remarkably consistent
across countries.
Conclusion
The majority of patients with asthma receiving mainte-
nance therapy who had had recent contact with their phy-
sician were found to have poor asthma control. Regardless
of the availability of effective medication, patients'
asthma continues to have a large impact on their health
and health-related quality of life. This study has shown
that patients recognise deteriorating asthma control and
are willing to self-treat episodes of worsening. However,
patients often adjust their medication in an inappropriate
manner, which represents a window of missed opportu-
nity. These findings demonstrate the need for a patient-
centred approach to asthma management in which
patients are educated to adjust their medication in a more
appropriate manner. This approach, combined with a
written personal action plan, has the potential to improve
asthma control.
Competing interests
MRP has received honoraria for lectures, educational
activities and ad hoc consultancies from AstraZeneca,
Vitaris, GSK and Novartis and research funding from the
AstraZeneca Foundation. TvdM has received research
grants from AstraZeneca, GSK and Altana, speakers' fees
from AstraZeneca, GSK, Altana and MSD, and has partici-
pated in advisory boards for Altana, AstraZeneca and Boe-
hringer Ingelheim. SEM received funding for travel to the
2005 European Respiratory Society congress, and hono-
raria from AstraZeneca for participating in a steering com-
mittee and for speaking at a press conference. WWB has
received research funds from AstraZeneca, Dynavax, Glax-
oSmithKline, Merck and sanofi-aventis. WWB has served
on advisory boards for AstraZeneca, Merck, Pfizer and
sanofi-aventis, has been a consultant to Dynavax, Scher-
ing, Merck and Wyeth, and a member of a steering com-
mittee for GlaxoSmithKline.
Authors' contributions
All authors formed the INSPIRE steering committee and
were involved in developing the questionnaire. M. R. Par-
tridge contributed to the conception and design of the
study, the analysis and interpretation of the data, and the
drafting of the paper. T. van der Molen, S.E. Myrseth and
W. W. Busse contributed to the design of the study and to
revising the paper critically. All authors made final deci-
sions on all aspects of the article and hence are in agree-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Pulmonary Medicine 2006, 6:13 http://www.biomedcentral.com/1471-2466/6/13
Page 9 of 9
(page number not for citation purposes)
ment with, and approve, the final version of the
submitted article.
Acknowledgements
We acknowledge the contribution of Sunil Ramkali (AstraZeneca R&D, 
Lund, Sweden) for input and guidance with the interpretation of results, and 
compilation of the manuscript. We also thank Julie Young, from Adelphi 
Communications Ltd, who provided medical writing support on behalf of 
AstraZeneca.
References
1. Masoli M, Fabian D, Holt S, Beasley R: Global burden of asthma.
[http://www.ginasthma.com/ReportItem.asp?l1=2&l2=2&intId=94].
Accessed: 21 June 2005
2. Global Initiative for Asthma: Global Strategy for Asthma Management
and Prevention (updated 2004) Bethesda MD: National Institutes of
Health; NIH Publication No. 02-3659; 2004. 
3. National Asthma Education and Prevention Program: Guidelines for the
Diagnosis and Management of Asthma Expert Panel Report 2 Bethesda,
MD: National Institutes of Health; NHI Publication No. 97-4051;
1997. 
4. British Thoracic Society: British guidelines on the management
of asthma.  Thorax 2003, 58(Suppl 1):1-94.
5. Hyland ME, Ståhl E: Asthma treatment needs: a comparison of
patients' and health care professionals' perceptions.  Clin Ther
2004, 26:2141-2152.
6. Aubier M, Pieters WR, Schlösser NJJ, Steinmetz K-O: Salmeterol/
fluticasone propionate (50/250 µg) in combination in a Dis-
kus® inhaler (Seretide®) is effective and safe in the treatment
of steroid-dependent asthma.  Respir Med 1999, 93:876-884.
7. Lalloo UG, Malolepszy J, Kozma D, Krofta K, Ankerst J, Johansen B,
Thomson NC: Budesonide and formoterol in a single inhaler
improves asthma control compared with increasing the dose
of corticosteroid in adults with mild-to-moderate asthma.
Chest 2003, 123:1480-1487.
8. Zetterström O, Buhl R, Mellem H, Perpina M, Hedman J, O'Neill S,
Ekstrom T: Improved asthma control with budesonide/for-
moterol in a single inhaler, compared with budesonide
alone.  Eur Respir J 2001, 18:262-268.
9. Price D, Ryan D, Pearce L, Bride F: The AIR study: asthma in real
life.  Asthma J 1999, 4:74-78.
10. Haughney J, Barnes G, Partridge M, Cleland J: The Living and
Breathing Study: a study of patients' views of asthma and its
treatments.  Primary Care Respiratory Journal 2004, 13:28-35.
11. Rabe KF, Vermeire PA, Soriano JB, Maier WC: Clinical manage-
ment of asthma in 1999: the Asthma Insights and Reality in
Europe (AIRE) study.  Eur Respir J 2000, 16:802-807.
12. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB,
Weiss ST: Worldwide severity and control of asthma in chil-
dren and adults: the global asthma insights and reality sur-
veys.  J Allergy Clin Immunol 2004, 114:40-47.
13. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie DR: Development and
validation of a questionnaire to measure asthma control.  Eur
Respir J 1999, 14:902-907.
14. Juniper EF, Svensson K, Mork AC, Ståhl E: Measurement proper-
ties and interpretation of three shortened versions of the
asthma control questionnaire.  Respir Med 2005, 99:553-558.
15. Juniper EF, Bousquet J, Abetz L, Bateman ED, the GOAL Committee:
Identifying 'well-controlled' and 'not well-controlled' asthma
using the Asthma Control Questionnaire.  Respir Med 2006,
100:616-624.
16. Hawkins G, McMahon AD, Twaddle S, Wood SF, Ford I, Thomson
NC: Stepping down inhaled corticosteroids in asthma; ran-
domised controlled trial.  BMJ 2003, 326:1115-1120.
17. Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA,
O'Byrne PM, Lofdahl CG, Pauwels RA, Ullman A: Exacerbations of
asthma: a descriptive study of 425 severe exacerbations. The
FACET International Study Group.  Am J Respir Crit Care Med
1999, 160:594-599.
18. FitzGerald JM, Becker A, Sears MR, Mink S, Chung K, Lee J, for the
Canadian Asthma Exacerbation Study Group: Doubling the dose of
budesonide versus maintenance treatment in asthma exac-
erbations.  Thorax 2004, 59:550-556.
19. Harrison TW, Oborne J, Newton S, Tattersfield AE: Doubling the
dose of inhaled corticosteroid to prevent asthma exacerba-
tions: randomised controlled trial.  Lancet 2004, 363:271-275.
20. Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood
P, Bauman A, Hensley MJ, Walters EH: Self-management educa-
tion and regular practitioner review for adults with asthma.
Cochrane Database Syst Rev 2003, 1:CD001117.
21. Foresi A, Morelli MC, Catena E: Low-dose budesonide with the
addition of an increased dose during exacerbations is effec-
tive in long-term asthma control.  Chest 2000, 117:440-446.
22. FitzGerald JM, Sears MR, Boulet LP, Becker AB, McIvor AR, Ernst P,
Smiljanic-Georgijev NM, Lee JS, Canadian Investigators: Adjustable
maintenance dosing with budesonide/formoterol reduces
asthma exacerbations compared with traditional fixed dos-
ing: a five-month multicentre Canadian study.  Can Respir J
2003, 10:427-434.
23. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y,
Ekstrom T, Bateman ED: Budesonide/formoterol combination
therapy as both maintenance and reliever medication.  Am J
Respir Crit Care Med 2005, 171:129-136.
24. Barnes PJ: A single inhaler for asthma?  Am J Respir Crit Care Med
2005, 171:95-96.
25. British Thoracic Society: Guidelines for management of asthma
in adults: I–Chronic persistent asthma. Statement by the
British Thoracic Society, Research Unit of the Royal College
of Physicians of London, King's Fund Centre, National
Asthma Campaign.  BMJ 1990, 301:651-653.
26. Aalbers R, Backer V, Kava TT, Omenaas ER, Sandstrom T, Jorup C,
Welte T: Adjustable maintenance dosing with budesonide/
formoterol compared with fixed-dose salmeterol/fluticasone
in moderate to severe asthma.  Curr Med Res Opin 2004,
20:225-240.
27. Gibson PG, Powell H: Written action plans for asthma: an evi-
dence-based review of the key components.  Thorax 2004,
59:94-99.
28. Thoonen BP, Schermer TR, Van Den Boom G, Molema J, Folgering H,
Akkermans RP, Grol R, Van Weel C, Van Schayck CP: Self-manage-
ment of asthma in general practice, asthma control and
quality of life: a randomised controlled trial.  Thorax 2003,
58:30-36.
29. Gallefoss F, Bakke PS: How does patient education and self-
management among asthmatics and patients with chronic
obstructive pulmonary disease affect medication?  Am J Respir
Crit Care Med 1999, 160:2000-2005.
30. Sibbald B: Patient self care in acute asthma.  Thorax 1989,
44:97-101.
31. Burr ML, Verrall C, Kaur B: Social deprivation and asthma.
Respir Med 1997, 91:603-608.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2466/6/13/prepub